Danggui-Shaoyao-San improves learning and memory in female SAMP8 via modulation of estradiol

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Huang, Yan ^a   Hu, Zeng Yao ^a   Yuan, Hui ^a   Shu, Lei ^a   Liu, Gang ^a   Qiao, Shan Yi ^a   Sun, Lei ^a   Zhou, Wen Xia ^a   Zhang, Yong Xiang ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; CHINESE DRUG; DANGGUI HAOYAO SAN EXTRACT; ESTRADIOL; GLYCINE; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; BRAIN TISSUE; COGNITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; FEMALE; HIPPOCAMPUS; LATENT PERIOD; LEARNING; MALE; MEMORY; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENESCENCE ACCELERATED MOUSE; STEP-DOWN PASSIVE AVOIDANCE; TREATMENT DURATION; VELOCITY;

EID: 84897550626     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/327294     Document Type: Article

References (78)

1. Cummings J. L., Alzheimer's disease. The New England Journal of Medicine 2004 351 1 56 67
2. Andersen K., Launer L. J., Dewey M. E., Letenneur L., Ott A., Copeland J. R. M., Dartigues J.-F., Kragh-Sorensen P., Baldereschi M., Brayne C., Lobo A., Martinez-Lage J. M., Stijnen T., Hofman A., Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. Neurology 1999 53 9 1992 1997 2-s2.0-0032786697
3. Jorm A. F., Jolley D., The incidence of dementia: a meta-analysis. Neurology 1998 51 3 728 733 2-s2.0-0031720801 (Pubitemid 28449250)
4. Ruitenberg A., Ott A., Van Swieten J. C., Hofman A., Breteler M. M. B., Incidence of dementia: does gender make a difference? Neurobiology of Aging 2001 22 4 575 580 2-s2.0-0034968974 10.1016/S0197-4580(01)00231-7 (Pubitemid 32607742)
5. Barnes L. L., Wilson R. S., Bienias J. L., Schneider J. A., Evans D. A., Bennett D. A., Sex differences in the clinical manifestations of Alzheimer disease pathology. Archives of General Psychiatry 2005 62 6 685 691 2-s2.0-20344371487 10.1001/archpsyc.62.6.685 (Pubitemid 40973444)
6. Corder E. H., Ghebremedhin E., Taylor M. G., Thal D. R., Ohm T. G., Braak H., The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Annals of the New York Academy of Sciences 2004 1019 24 28 2-s2.0-3242682466 10.1196/annals.1297.005 (Pubitemid 38951278)
7. Swaab D. F., Chung W. C. J., Kruijver F. P. M., Hofman M. A., Ishunina T. A., Structural and functional sex differences in the human hypothalamus. Hormones and Behavior 2001 40 2 93 98 2-s2.0-0034848121 10.1006/hbeh.2001.1682 (Pubitemid 32846338)
8. Buckwalter J. G., Sobel E., Dunn M. E., Diz M. M., Henderson V. W., Gender differences on a brief measure of cognitive functioning in Alzheimer's disease. Archives of Neurology 1993 50 7 757 760 2-s2.0-0027198902 (Pubitemid 23203583)
9. Henderson V. W., Buckwalter J. G., Cognitive deficits of men and women with Alzheimer's disease. Neurology 1994 44 1 90 96 2-s2.0-0028053251 (Pubitemid 24029436)
10. Sinforiani E., Citterio A., Zucchella C., Bono G., Corbetta S., Merlo P., Mauri M., Impact of gender differences on the outcome of alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2010 30 2 147 154 2-s2.0-77956090035 10.1159/000318842
11. Manly J. J., Merchant C. A., Jacobs D. M., Small S. A., Bell K., Ferin M., Mayeux R., Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 2000 54 4 833 837 2-s2.0-0034700965 (Pubitemid 30111338)
12. Rosario E. R., Chang L., Head E. H., Stanczyk F. Z., Pike C. J., Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease. Neurobiology of Aging 2011 32 4 604 613 2-s2.0-79953116520 10.1016/j.neurobiolaging.2009.04.008
13. Yue X., Lu M., Lancaster T., Cao P., Honda S.-I., Staufenbiel M., Harada N., Zhong Z., Shen Y., Li R., Brain estrogen deficiency accelerates A β plaque formation in an Alzheimer's disease animal model. Proceedings of the National Academy of Sciences of the United States of America 2005 102 52 19198 19203 2-s2.0-30044438885 10.1073/pnas.0505203102 (Pubitemid 43049589)
14. Carroll J. C., Pike C. J., Selective estrogen receptor modulators differentially regulate Alzheimer-like changes in female 3xTg-AD mice. Endocrinology 2008 149 5 2607 2611 2-s2.0-42449163010 10.1210/en.2007-1346 (Pubitemid 351574524)
15. Levin-Allerhand J. A., Lominska C. E., Wang J., Smith J. D., 17 α -estradiol and 17 β -estradiol treatments are effective in lowering cerebral amyloid- β levels in A β PPSWE transgenic mice. Journal of Alzheimer's Disease 2002 4 6 449 457 2-s2.0-0036967245 (Pubitemid 36142834)
16. Petanceska S. S., Nagy V., Frail D., Gandy S., Ovariectomy and 17 β -estradiol modulate the levels of Alzheimer's amyloid β peptides in brain. Neurology 2000 54 12 2212 2217 2-s2.0-0034720686 (Pubitemid 30416268)
17. Xu H., Wang R., Zhang Y.-W., Zhang X., Estrogen, β -amyloid metabolism/trafficking, and Alzheimer's disease. Annals of the New York Academy of Sciences 2006 1089 324 342 2-s2.0-33847777848 10.1196/annals.1386.036 (Pubitemid 47092091)
18. Fujii T., Herbal factors in the treatment of autoimmunity-related habitual abortion. Vitamins and Hormones 2002 65 333 344 2-s2.0-0036050868 (Pubitemid 135763180)
19. Hagino N., An overview of Kampo medicine: Toki-Shakuyaku-San (TJ-23). Phytotherapy Research 1993 7 6 391 394
20. Higaki S., Toyomoto T., Morohashi M., Seijo-bofu-to, Jumi-haidoku-to and Toki-shakuyaku-san suppress rashes and incidental symptoms in acne patients. Drugs under Experimental and Clinical Research 2002 28 5 193 196 2-s2.0-0037004990 (Pubitemid 36267945)
21. Inanaga K., Aging in brain and mind-drug therapy for patients with Behavioral and Psychological Symptoms of Dementia (BPSD). Seishin Shinkeigaku Zasshi 2007 109 7 703 708 2-s2.0-38449111343
22. Kotani N., Oyama T., Sakai I., Hashimoto H., Muraoka M., Ogawa Y., Matsuki A., Analgesic effect of a herbal medicine for treatment of primary dysmenorrhea -A Double-Blind Study. American Journal of Chinese Medicine 1997 25 2 205 212 2-s2.0-0030630080 (Pubitemid 127758152)
23. Chung M. H., Suzuki S., Nishihara T., Hattori M., Estrogenic effects of a Kampo formula, Tokishakuyakusan, in parous ovariectomized rats. Biological and Pharmaceutical Bulletin 2008 31 6 1145 1149 2-s2.0-45749102514 10.1248/bpb.31.1145 (Pubitemid 351871166)
24. Usuki S., Tokishakuyakusan stimulates progesterone and estradiol-17 beta production by rat granulosa cells and progesterone, testosterone and estradiol-17 beta by the residual portion of the follicle in vitro. American Journal of Chinese Medicine 1991 19 2 155 161 2-s2.0-0026272264
25. Mizushima N., Effects of TJ-23 (Toki-shakuyaku-san) on senile dementia. Japanese Medical and Pharmaceutical Society for WAKAN-YAKU 1989 6 456 457
26. Egashira N., Iwasaki K., Akiyoshi Y., Takagaki Y., Hatip-Al-Khatib I., Mishima K., Kurauchi K., Ikeda T., Fujiwara M., Protective effect of Toki-shakuyaku-san on amyloid β 25-35- induced neuronal damage in cultured rat cortical neurons. Phytotherapy Research 2005 19 5 450 453 2-s2.0-24644504769 10.1002/ptr.1671 (Pubitemid 41285016)
27. Itoh T., Michijiri S., Murai S., Saito H., Nakamura K., Itsukaichi O., Fujiwara H., Ookubo N., Saito H., Regulatory effect of danggui-shaoyao-san on central cholinergic nervous system dysfunction in mice. American Journal of Chinese Medicine 1996 24 3-4 205 217 2-s2.0-0030331554 (Pubitemid 126764446)
28. Kitabayashi Y., Shibata K., Nakamae T., Narumoto J., Fukui K., Effect of traditional Japanese herbal medicine toki-shakuyaku-san for mild cognitive impairment: SPECT Study. Psychiatry and Clinical Neurosciences 2007 61 4 447 448 2-s2.0-34347372911 10.1111/j.1440-1819.2007.01680.x (Pubitemid 47019914)
29. Mizushima Y., Kan S., Yoshida S., Irie Y., Urata Y., Effect of Choto-san, a Kampo medicine, on impairment of passive avoidance performance in senescence accelerated mouse (SAM). Phytotherapy Research 2003 17 5 542 545 2-s2.0-0038526370 10.1002/ptr.1193 (Pubitemid 36605909)
30. Ueda Y., Komatsu M., Hiramatsu M., Free radical scavenging activity of the Japanese herbal medicine Toki-Shakuyaku-San (TJ-23) and its effect on superoxide dismutase activity, lipid peroxides, glutamate, and monoamine metabolites in aged rat brain. Neurochemical Research 1996 21 8 909 914 2-s2.0-0029853553
31. Hu Z.-Y., Liu G., Cheng X.-R., Huang Y., Yang S., Qiao S.-Y., Sun L., Zhou W.-X., Zhang Y.-X., JD-30, an active fraction extracted from Danggui-Shaoyao-San, decreases β -amyloid content and deposition, improves LTP reduction and prevents spatial cognition impairment in SAMP8 mice. Experimental Gerontology 2012 47 1 14 22 2-s2.0-84155172500 10.1016/j.exger. 2011.09.009
32. Hu Z.-Y., Liu G., Yuan H., Yang S., Zhou W.-X., Zhang Y.-X., Qiao S.-Y., Danggui-Shaoyao-San and its active fraction JD-30 improve A β -induced spatial recognition deficits in mice. Journal of Ethnopharmacology 2010 128 2 365 372 2-s2.0-77649193490 10.1016/j.jep.2010.01.046
33. Huang Y., Zhou W., Zhang Y., Bright lighting conditions during testing increase thigmotaxis and impair water maze performance in BALB/c mice. Behavioural Brain Research 2012 226 1 26 31 2-s2.0-80053172003 10.1016/j.bbr.2011.08.043
34. Marzinzig M., Nussler A. K., Stadler J., Marzinzig E., Barthlen W., Nussler N. C., Beger H. G., Morris S. M. Jr., Brückner U. B., Improved methods to measure end products of nitric oxide in biological fluids: nitrite, nitrate, and S-nitrosothiols. Nitric Oxide 1997 1 2 177 189 2-s2.0-0031424178 10.1006/niox.1997.0116 (Pubitemid 28076558)
35. Feldman P. L., The surprising life of nitric oxide. Chemical and Engineering News 1993 71 51 26 38 2-s2.0-33751386517
36. Moncada S., Palmer R. M. J., Higgs E. A., Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Reviews 1991 43 2 109 142 2-s2.0-0025883342
37. Rao A. M., Dogan A., Hatcher J. F., Dempsey R. J., Fluorometric assay of nitrite and nitrate in brain tissue after traumatic brain injury and cerebral ischemia. Brain Research 1998 793 1-2 265 270 2-s2.0-0032543101 10.1016/S0006-8993(98)00183-8 (Pubitemid 28294093)
38. Hashimoto K., Sawa A., Iyo M., Increased levels of glutamate in brains from patients with mood disorders. Biological Psychiatry 2007 62 11 1310 1316 2-s2.0-35848939420 10.1016/j.biopsych.2007.03.017 (Pubitemid 350060893)
39. Nomura Y., Okuma Y., Age-related defects in lifespan and learning ability in SAMP8 mice. Neurobiology of Aging 1999 20 2 111 115 2-s2.0-0033102614 10.1016/S0197-4580(99)00006-8 (Pubitemid 29488721)
40. Nomura Y., Yamanaka Y., Kitamura Y., Arima T., Ohnuki T., Oomura Y., Sasaki K., Nagashima K., Ihara Y., Senescence-accelerated mouse. Neurochemical studies on aging. Annals of the New York Academy of Sciences 1996 786 410 418 2-s2.0-0029762701
41. Chen G.-H., Wang Y.-J., Wang X.-M., Zhou J.-N., Accelerated senescence prone mouse-8 shows early onset of deficits in spatial learning and memory in the radial six-arm water maze. Physiology and Behavior 2004 82 5 883 890 2-s2.0-4644245973 10.1016/j.physbeh.2004.07.008 (Pubitemid 39297085)
42. Takeda T., Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiology of Aging 1999 20 2 105 110 2-s2.0-0032847560 10.1016/S0197-4580(99)00008-1 (Pubitemid 29488720)
43. Miyamoto M., Characteristics of age-related behavioral changes in senescence- accelerated Mouse SAMP8 and SAMP10. Experimental Gerontology 1997 32 1-2 139 148 2-s2.0-0030896788 10.1016/S0531-5565(96)00061-7 (Pubitemid 27131713)
44. Takeda T., Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochemical Research 2009 34 4 639 659 2-s2.0-62349123068 10.1007/s11064-009-9922-y
45. Okuma Y., Nomura Y., Senescence-accelerated mouse (SAM) as an animal model of senile dementia: pharmacological, neurochemical and molecular biological approach. Japanese Journal of Pharmacology 1998 78 4 399 404 2-s2.0-0032421523 10.1254/jjp.78.399 (Pubitemid 29052060)
46. Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002 297 5580 353 356 2-s2.0-0037135111 10.1126/science.1072994 (Pubitemid 34790756)
47. Carroll J. C., Rosario E. R., The potential use of hormone-based therapeutics for the treatment of Alzheimer's disease. Current Alzheimer Research 2012 9 1 18 34 2-s2.0-84856483459 10.2174/156720512799015109
48. Pike C. J., Carroll J. C., Rosario E. R., Barron A. M., Protective actions of sex steroid hormones in Alzheimer's disease. Frontiers in Neuroendocrinology 2009 30 2 239 258 2-s2.0-67449141652 10.1016/j.yfrne.2009.04. 015
49. Amtul Z., Wang L., Westaway D., Rozmahel R. F., Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease. Neuroscience 2010 169 2 781 786 2-s2.0-77954623481 10.1016/j.neuroscience.2010. 05.031
50. Desdouits-Magnen J., Desdouits F., Takeda S., Syu L.-J., Saltiel A. R., Buxbaum J. D., Czernik A. J., Nairn A. C., Greengard P., Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. Journal of Neurochemistry 1998 70 2 524 530 2-s2.0-0031952526 (Pubitemid 28079341)
51. Jaffe A. B., Toran-Allerand C. D., Greengard P., Gandy S. E., Estrogen regulates metabolism of Alzheimer amyloid β precursor protein. Journal of Biological Chemistry 1994 269 18 13065 13068 2-s2.0-0028342424 (Pubitemid 24206062)
52. Manthey D., Heck S., Engert S., Behl C., Estrogen induces a rapid secretion of amyloid β precursor protein via the mitogen-activated protein kinase pathway. European Journal of Biochemistry 2001 268 15 4285 4291 2-s2.0-0034818022 10.1046/j.1432-1327.2001.02346.x (Pubitemid 32862889)
53. Thakur M. K., Mani S. T., Estradiol regulates APP mRNA alternative splicing in the mice brain cortex. Neuroscience Letters 2005 381 1-2 154 157 2-s2.0-18844457578 10.1016/j.neulet.2005.02.014 (Pubitemid 40693160)
54. Cooke B. M., Woolley C. S., Gonadal hormone modulation of dendrites in the mammalian CNS. Journal of Neurobiology 2005 64 1 34 46 2-s2.0-20544469438 10.1002/neu.20143 (Pubitemid 40847429)
55. Foy M. R., Baudry M., Akopian G. K., Thompson R. F., Regulation of hippocampal synaptic plasticity by estrogen and progesterone. Vitamins and Hormones 2010 82 219 239 2-s2.0-77955881216 10.1016/S0083-6729(10)82012-6
56. Gibbs R. B., Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocrine Reviews 2010 31 2 224 253 2-s2.0-77952908171 10.1210/er.2009-0036
57. Simpkins J. W., Yi K. D., Yang S.-H., Dykens J. A., Mitochondrial mechanisms of estrogen neuroprotection. Biochimica et Biophysica Acta 2010 1800 10 1113 1120 2-s2.0-77956176352 10.1016/j.bbagen.2009.11.013
58. Suzuki S., Brown C. M., Wise P. M., Neuroprotective effects of estrogens following ischemic stroke. Frontiers in Neuroendocrinology 2009 30 2 201 211 2-s2.0-67349251253 10.1016/j.yfrne.2009.04.007
59. Henderson V. W., Paganini-Hill A., Emanuel C. K., Dunn M. E., Buckwalter J. G., Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and nondemented control subjects. Archives of Neurology 1994 51 9 896 900 2-s2.0-0028086440 (Pubitemid 24286044)
60. Hogervorst E., Boshuisen M., Riedel W., Willeken C., Jolles J., The effect of hormone replacement therapy on cognitive function in elderly women. Psychoneuroendocrinology 1999 24 1 43 68 2-s2.0-0032904437 10.1016/S0306- 4530(98)00043-2 (Pubitemid 29057019)
61. Leblanc E. S., Janowsky J., Chan B. K. S., Nelson H. D., Hormone replacement therapy and cognition: systematic review and meta-analysis. Journal of the American Medical Association 2001 285 11 1489 1499 2-s2.0-0035925762 (Pubitemid 32221898)
62. Paganini-Hill A., Oestrogen replacement therapy and Alzheimer's disease. British Journal of Obstetrics and Gynaecology, Supplement 1996 103 13 80 86 2-s2.0-0029896796 (Pubitemid 26163455)
63. Zandi P. P., Carlson M. C., Plassman B. L., Welsh-Bohmer K. A., Mayer L. S., Steffens D. C., Breitner J. C. S., Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. Journal of the American Medical Association 2002 288 17 2123 2129 2-s2.0-0037032401 10.1001/jama.288.17.2123 (Pubitemid 35265379)
64. Schuman E. M., Madison D. V., A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science 1991 254 5037 1503 1506 2-s2.0-0026326187 (Pubitemid 21917489)
65. Jeynes B., Provias J., Significant negative correlations between capillary expressed eNOS and Alzheimer lesion burden. Neuroscience Letters 2009 463 3 244 248 2-s2.0-68949202838 10.1016/j.neulet.2009.07.091
66. Hisamoto K., Bender J. R., Vascular cell signaling by membrane estrogen receptors. Steroids 2005 70 5-7 382 387 2-s2.0-18144392728 10.1016/j.steroids. 2005.02.011 (Pubitemid 40616036)
67. Zhao Y., Zhou G., Wang J., Paeoniflorin protects against ANIT-induced cholestasis by ameliorating oxidative stress in rats. Food and Chemical Toxicology 2013 58 242 248
68. Nam K. N., Yae C. G., Hong J. W., Paeoniflorin, a monoterpene glycoside, attenuates lipopolysaccharide-induced neuronal injury and brain microglial inflammatory response. Biotechnology Letters 2013 35 8 1183 1189
69. Morris R. G. M., Anderson E., Lynch G. S., Baudry M., Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 1986 319 6056 774 776 2-s2.0-0022650213 (Pubitemid 16145031)
70. Tsien J. Z., Huerta P. T., Tonegawa S., The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 1996 87 7 1327 1338 2-s2.0-0030446363 10.1016/S0092-8674(00)81827-9 (Pubitemid 27010115)
71. Yashiro K., Philpot B. D., Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 2008 55 7 1081 1094 2-s2.0-54049087697 10.1016/j.neuropharm.2008.07.046
72. Rupsingh R., Borrie M., Smith M., Wells J. L., Bartha R., Reduced hippocampal glutamate in Alzheimer disease. Neurobiology of Aging 2011 32 5 802 810 2-s2.0-79954569500 10.1016/j.neurobiolaging.2009.05.002
73. Hashimoto K., Fukushima T., Shimizu E., Possible role of D-serine in the pathophysiology of Alzheimer's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004 28 2 385 388 (Pubitemid 38130146)
74. Yang S., Qiao H., Wen L., Zhou W., Zhang Y., D-Serine enhances impaired long-term potentiation in CA1 subfield of hippocampal slices from aged senescence-accelerated mouse prone/8. Neuroscience Letters 2005 379 1 7 12 2-s2.0-16244413228 10.1016/j.neulet.2004.12.033 (Pubitemid 40462388)
75. Huang Y., Zhang H., Yang S., Qiao H., Zhou W., Zhang Y., Liuwei Dihuang decoction facilitates the induction of long-term potentiation (LTP) in senescence accelerated mouse/prone 8 (SAMP8) hippocampal slices by inhibiting voltage-dependent calcium channels (VDCCs) and promoting N-methyl-D-aspartate receptor (NMDA) receptors. Journal of Ethnopharmacology 2012 140 2 384 390 2-s2.0-84858008861 10.1016/j.jep.2012.01.030
76. Harada K., Nakato K., Yarimizu J., Yamazaki M., Morita M., Takahashi S., Aota M., Saita K., Doihara H., Sato Y., Yamaji T., Ni K., Matsuoka N., A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3- pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. European Journal of Pharmacology 2012 685 1-3 59 69 2-s2.0-84860593966 10.1016/j.ejphar.2012.04.013
77. Komatsu M., Ueda Y., Hiramatsu M., Different changes in concentrations of monoamines and their metabolites and amino acids in various brain regions by the herbal medicine/Toki- Shakuyaku-San between female and male senescence-accelerated mice (SAMP8). Neurochemical Research 1999 24 7 825 831 2-s2.0-0033034489 10.1023/A:1020945611673 (Pubitemid 29296257)
78. Kobertson G. L., Hagerman D. D., Richardson G. S., Villee C. A., Estradiol stimulation of glycine incorporation by human endometrium in tissue culture. Science 1961 134 3494 1986 1987 2-s2.0-37049243455